The blood-brain tumor barrier (BTB) limits the delivery of therapeutic drugs to brain tumors. We demonstrate in a rat brain tumor (RG2) model an enhanced drug delivery to brain tumor following intracarotid infusion of bradykinin (BK), nitric oxide (NO) donors, or agonists of soluble guanylate cyclase (sGC) and calcium-dependent potassium (K Ca ) channels. We modulated K Ca channels by specific agonists and agents that produce NO and cGMP in situ to obtain sustained enhancement of selective drug delivery to brain tumors. Immunoblot and immunolocalization studies demonstrate overexpression of K Ca channels in tumor cells and capillaries compared with normal brain. The potentiometric assays demonstrate the functional activity of K Ca channels in rat brain endothelial and glioma cells. Additionally, we show that BK and NS-1619 significantly increased the density of transport vesicles in the cytoplasm of brain tumor capillary endothelia and tumor cells. The cleft indices and cleft area indices in rat tumor capillaries were significantly higher than in normal brain capillaries, and BK infusion did not alter these indices. These data demonstrate that the cellular mechanism for K Ca channel-mediated BTB permeability increase is due to accelerated formation of pinocytotic vesicles, which can transport drugs across BTB. We conclude that K Ca channels serve as a convergence point in the biochemical regulation of BTB permeability.
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The blood-brain tumor barrier (BTB), formed by brain tumor capillaries, significantly limits delivery of therapeutic drugs to brain tumors (Groothuis, 2000) . During the past decade, a considerable effort has been made and various strategies have been used to deliver selectively therapeutic drugs to brain tumors and injured brain. We developed the biochemical approach to increase BTB permeability and to enhance delivery of therapeutic drugs or small-to large-sized substances to brain tumors, including contrast-enhancing agents, antitumor compounds, therapeutic proteins, and viral vectors Nakano et al., 1996; Black et al., 1997; Matsukado et al., 1998; Rainov et al., 1998; Sugita and Black, 1998) , to brain tumors selectively, with little or no drug delivery to the normal brain. This drug delivery strategy exploits the responsiveness of brain tumor capillaries to intravascular infusion of low doses of vasomodulators, such as bradykinin (BK), causing BTB permeability increase via a mechanism involving BK type 2 (B2) receptors , nitric oxide (NO) (Nakano et al., 1996) , cGMP , and calciumdependent potassium (K Ca ) channels (Fig. 1) .
BK-induced changes in BTB permeability are transient Matsukado et al., 1998) and variable (Black et al., 1997) . For example, the BK analog RMP-7 elicited a varying BTB permeability increase in patients with glioblastoma multiforme (Black et al., 1997) . In the subsequent study (Liu et al., 2001b) , we showed varying B2 receptor expression in different types of rat brain tumors, which correlated with varying responses to BK. Moreover, refractoriness of BTB response to prolonged infusion of BK , possibly due to B2 receptor internalization (Pizard et al., 1999) , prompted us to identify additional molecular targets and cellular mechanisms to achieve consistent and selective drug delivery to brain tumors.
Recent evidence suggests that K Ca channels are present in cerebral blood vessels to regulate cerebral blood vessel tone (Kitazono et al., 1995) and, probably, BBB permeability. K Ca channels in brain are inhibited by iberiotoxin (IBTX), a highly specific (IC 50 ϭ 68 pM) inhibitor (Wanner et al., 1999) . K Ca channel activity is triggered by depolarization and enhanced by an increase in cytosolic Ca 2ϩ (Faraci and Heistad, 1998) . Endothelium-dependent regulation of cerebral blood vessel functions is impaired in brain tumors (Cobbs et al., 1995) , which might affect tumor capillary permeability in response to vasomodulators.
Evidence is accumulating that K Ca channels play an important role in vasodilation mediated by BK (Berg and Koteng, 1997; Sobey et al., 1997) , NO-donors (Bolotina et al., 1994) , cGMP (Robertson et al., 1993; Lohse et al., 1998) , and soluble guanylate cyclase (sGC) activators (Koesling, 1998) . BK is thought to increase intracellular calcium ([Ca 2ϩ ] i ), which could activate K Ca channels, and alter membrane potential in cells (Miura et al., 1999) . In brain endothelial cells, BK-induced K Ca channel activation was potentiated by NS-1619, a selective agonist (EC 50 ϭ 20 nM) for K Ca channels (Nelson and Quayle, 1995) , and attenuated by IBTX (Miura et al., 1999) . We performed immunoblot and immunolocalization studies in rat cerebral capillary endothelial and tumor cells to elucidate differential responses of the BTB to K Ca channel modulators. We also investigated the functional presence of putative K Ca channels in rat brain endothelial and tumor cells by measuring the membrane potential changes induced by K Ca channel modulators.
Brain capillary endothelial cells form "tight junctions" that are thought to regulate, in part, the movement of molecules across the blood brain barrier (BBB) and BTB. Using transmission electron microscopy, we investigated whether BK and NS-1619 induce accelerated formation of transport vesicles in both brain tumor capillary endothelium and tumor cells. Previously, a cGMP analog, dibutyryl cGMP (dbcGMP), was shown to increase the number of transcytotic vesicles in the normal cerebral capillary endothelium, possibly by K Ca channel modulation (Joo et al., 1983) . Stewart et al. (1987) , however, reported an increased density of microvessel endothelial vesicles in human brain tumors. Moreover, a direct correlation between increased BTB permeability and vesicle formation has been shown in brain tumor capillaries (Stewart, 2000) . We investigated whether K Ca channels mediate increase in BTB permeability in response to BK or NS-1619 and whether such permeability increase is by increased endothelial tight junctions or accelerated transcytotic vesicle formation in tumor capillary endothelium. Additionally, we investigated whether BK and NS-1619 enhance transendothelial vesicular transport to a tracer, horseradish peroxidase (HRP), across the luminal-abluminal axis of tumor capillary endothelium. Herein, we report that K Ca channels mediate the effect of BK, cGMP, NO donors, and sGC activators and therefore serve as a crucial target protein in the regulation of BTB permeability. 
Materials and Methods
were used for the present study. The activators used (shown in blue) include BK Black et al., 1997) , the guanylate cyclase activator YC-1, NO donors (Ningaraj et al., 2000) , and K Ca channel opener NS-1619 (Ningaraj et al., 2001 ). The inhibitors used (shown in red) include B2 receptor antagonist HOE140 , NOS inhibitor N -nitro-L-arginine methyl ester (Nakano et al., 1996) , the guanylate cyclase inhibitor ODQ , the phosphodiesterase inhibitor zaprinast , and the K Ca channel inhibitor IBTX (Miura et al., 1999) .
In Vivo BBB/BTB Permeability. All animal experiments were conducted in accordance with policies set by the Institutional Animal Care and Usage Committee and NIH (Bethesda, MD) guidelines. A rat xenograft tumor model was prepared using female Wistar rats weighing 180 to 200 g for BBB/BTB permeability studies, as described earlier . In brief, rats received an intracerebral injection of 1 ϫ 10 5 RG2 cells in 5 l of medium with 1.2% methyl cellulose using a Hamilton syringe. The coordinates were 5 mm lateral to the bregma and 4.5 mm deep to the basal ganglia. RG2 cells were maintained in a monolayer culture in F-12 medium with 10% calf serum. Seven days after the tumor implantation, the rats were anesthetized with an i.p. injection of ketamine/ xylazine. A polyethylene catheter was inserted retrograde through the external carotid artery into the common carotid artery until the bifurcation, ipsilateral to the tumor. The pterygopalatine artery was cauterized. A femoral vein was cannulated to administer [ 14 C]AIB. In regional permeability studies, 5 min after the start of the intracarotid infusion, 100 Ci/kg [ 14 C]AIB in 1 ml of PBS was injected as an intravenous bolus within a 5-s period. Arterial blood pressure was monitored throughout the experimental period with a blood pressure monitor (DigiMed, Louisville, KY) using the catheter surgically inserted into right femoral artery. Hematocrit and arterial blood gases, pCO 2 and pO 2 , were measured with a blood gas machine (Bayer Diagnostics, Tarrytown, NY) using blood drawn from the catheter inserted in the left femoral artery for the purpose of a continuous blood draw. Cerebral laser-Doppler flowmetry (LDF) is a semiquantitative measure of cerebral blood flow (CBF) at a given area (Watanabe et al., 2001) . To determine whether infusion of vasomodulators affect CBF at the tumor area, we performed LDF using a laser-Doppler (DRT4; Moore Instruments Ltd., Devon, England) equipped with a DP3 optical (1-mm diameter) probe during a 15-min intracarotid infusion of vasomodulators in some rats (n ϭ 3/group). A shallow indentation was made on the skull above the right brain hemisphere with a low-speed drill for placement of the single-laser fiber probe (sensitive up to 2-3 mm deep). The LDF signal was recorded continuously during intracarotid infusion of vehicle or vasomodulators. Rats with abnormal CBF, blood gases, or blood pressure were excluded from the study.
K i Measurement. The unilateral transfer constant K i (microliters per gram per minute) was determined for radiotracer [
14 C]AIB in the tumor core, tumor-adjacent brain tissue, and contralateral brain tissue. The BBB permeability constant for [ 14 C]AIB was determined using the quantitative autoradiographic (QAR) method . The K i , which is an initial rate for blood-to-brain transfer of the tracer, was calculated by the method of Ohno et al. (1978) . An optimum dose of BK (10 g/kg/min), which was established in earlier studies Sugita and Black, 1998) , was used for K i measurements. Additionally, in a separate QAR study, varying doses of IBTX (0 -0.52 g/kg/min) were used to establish an optimal dose, which maximally attenuates the BK (10 g/kg/min)-induced BTB permeability increase in RG2 tumor-bearing rats. Additional experiments were performed in rats with RG2 tumor by coinfusing NS-1619, DEA-NONOate, PAPA-NONOate, or YC-1 with IBTX (0.26 g/kg/min) to investigate whether inhibition of K Ca channels by IBTX attenuates permeability increases induced by these vasomodulators. Dose Response Study. To establish the optimal and safe dose that selectively increases BTB permeability without appreciably altering systemic blood pressure, varying doses (0 -60 g/kg/min) of NS-1619 were used in a separate QAR study. Similarly, optimum doses of DEA-NONOate, PAPA-NONOate, or YC-1 that did not significantly affect systemic blood pressure were determined by Evans blue delivery studies in rats with RG2 tumors.
Time Course. To determine whether vasomodulator-induced BTB permeability increase in RG2 tumor-bearing rat was transient or could be sustained over a longer period, a separate QAR study was performed. BK (10 g/kg/min), NS-1619 (26.66 g/kg/min), or DEANONOate was intracarotidly infused separately for 15-, 30-, and 60-min periods, and K i determined as described above.
Isolation of Brain Microvessels. To demonstrate the presence of K Ca channels in rat brain capillaries, we isolated microcapillaries from rat brain using the method of Pardridge et al. (1985) , with slight modifications. In brief, cortex (approximately 10 g) obtained from 20 female Wistar rat brains was washed with DMEM to remove meninges and superficial vessels. The tissue was minced and suspended in 20 ml of DMEM, and dispase was added to a final concentration of 0.5%. The suspension was placed at 37°C with constant stirring for 2 h, and the homogenate was centrifuged (1000g at 4°C for 20 min). The pellet was resuspended in 25 ml of DMEM containing 13% Dextran (molecular mass, 70 kDa) and centrifuged at 7000g for 20 min at 4°C. The pellet was resuspended in 5 ml of DMEM and passed through 200-m Nylon mesh to retain microvessels and red cells, which were concentrated by centrifugation at 5000g for 10 min at 4°C. The pellet was resuspended in 2 ml of DMEM, laid on the top of a pre-established 50% Percoll gradient in Medium-199 (Invitrogen, Carlsbad, CA) and 30 mM Na-HEPES, pH 7.4, and centrifuged at 1000g at 4°C for 10 min. The middle layer, rich in microvessels, was collected and washed with DMEM to remove Percoll. This process was repeated once more to separate most of the contaminating red cells. The morphology of the microvessels was verified under a light microscope and stored at Ϫ180°C in a cryopreservation solution containing physiological buffer with 14% glycerol and 1.4% sorbitol, pH 7.4, until further use.
Preparation of Capillary Endothelial Cells. To investigate the expression of K Ca channels in rat brain endothelial (RBE) cells, we isolated endothelial cells from the brains of neonatal rats using a modified method after Estrada et al. (1990) . Briefly, the brains were rinsed with PBS, minced, and cleaned of meninges and superficial vessels. The tissue was homogenized and serially sieved through 70-and 20-m Nylon meshes. The material retained was digested overnight with 1 mg/ml collagenase (Roche Molecular Biochemicals, Indianapolis, IN) in a shaker incubator at 37°C and centrifuged (1000g for 30 min). The pellet was resuspended in trypsin-EDTA (0.05% and 0.53 mM, respectively) for 30 min at 37°C. The sample was then centrifuged at 1000g for 30 min. To suppress the growth of astrocytes, the pellet was resuspended in culture medium [minimal essential medium containing D-valine, 20% fetal calf serum, 1% penicillin-streptomycin, 0.6% L-glutamine, 0.1% endothelial cell growth supplement (Upstate Biotechnology, Lake Placid, NY), and 0.1 M dexamethasone] and plated in collagen-coated culture flasks. Culture medium was replaced every 24 h until a confluent monolayer of endothelial cells was formed. The homogeneity (Ͼ90 -95%) of endothelial cells was verified by immunostaining with v. Willebrandt factor (Factor VIII; Dako Diagnostika, Hamburg, Germany). For potentiometric assays, RBE cells were seeded in a gelatin-coated, 96-well plate to obtain a monolayer.
Immunohistochemistry. For immunohistochemical studies, rats with intracerebral RG2 tumors were perfused transcardially with 0.1 M Tris/HCl-buffered saline (TBS), and brains were fixed with 4% paraformaldehyde in TBS buffer. Serial sections (15-20 m thick) of brain were cut on a cryostat, washed in PBS, treated with or without 0.2% Triton X-100 for 10 min, and washed three times in TBS. Nonspecific binding sites on brain sections were blocked with 3% normal goat serum in TBS for 4 h. To determine whether K Ca channels are present on capillary endothelial and tumor cells, brain tumor sections were incubated with a polyclonal anti-K Ca channel antibody raised against its ␣-subunit, and anti-Factor VIII monoclonal primary antibody. The colocalization of K Ca channels and Factor VIII was accomplished with FITC and rhodamine-conjugated secondary antibodies using fluorescence and confocal microscopes. To demonstrate the expression of K Ca channels in different rat glioma cells, a monolayer of RG2, C6, and 9L cells fixed with 4% paraformaldehyde were processed similarly and immunolocalized with anti-K Ca channel polyclonal primary antibody and secondary IgG conjugated to either FITC or rhodamine. In addition, immunolocalization of K Ca channels and Factor VIII was performed in a monolayer of primary RBE cells. To investigate the differential expression of K Ca channels by Western blot analyses, the extracts of normal brain and tumor tissues obtained from Wistar rats, which harbored intracerebral RG2 tumor for 7 to 10 days post RG2 cell implantation, were used. Immunoblot analysis was also performed on RG2 cells, RBE cells, and rat brain capillaries. The samples for Western blot analyses were prepared after three washes with PBS and lysis in lysing buffer (50 mM Tris-HCl, pH 8.0, 20 mM EDTA, 0.1% Triton X-100, and 100 mM NaCl). The protein concentration of the samples was determined using a Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA). The samples, containing 20 g of protein, were boiled for 5 min and subjected to electrophoresis on 8% SDS-polyacrylamide gel electrophoresis. After the transfer of protein onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA), the membrane was incubated in blocking buffer (5% nonfat dairy milk in PBS) for 2 h at ambient temperature and probed with affinity-purified polyclonal anti-K Ca channel primary antibody (1:500) in the blocking buffer overnight at 4°C. The membrane was washed four times with 0.1% Tween-20 in PBS, probed with the secondary antibody in the blocking buffer for 1 h at ambient temperature, and washed again with 0.1% Tween-20 in PBS. The signals were detected with an enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Piscataway, NJ). The polyclonal primary anti-K Ca channel antibody raised against a pore-forming 125-kDa ␣-subunit peptide sequence (1118 -1135) was a generous gift from Dr. Knaus (University of Innsbruck, Innsbruck, Austria). Anti-␤-actin monoclonal antibody was obtained from Santa Cruz Biotech (Santa Cruz, CA).
Confocal Microscopy and Image Analysis for Visualization of K Ca Channels. Images were captured using a Leica (Mannheim, Germany) TCS SP laser-scanning confocal microscope (inverted) equipped with argon (Ar; 488 nm) and krypton (Kr; 568 nm) lasers. FITC signals for K Ca channels expressed on cultured rat endothelial cells, glioma cells, or RG2 tumor-bearing rat brain sections were visualized using the 488-nm Ar laser line, and TRITC signals for Factor VIII were visualized using the 568-nm Kr laser line. Fluorescence signals for FITC and TRITC were displayed individually as green and red pseudo-color projections or merged as overlay projections to visualize possible colocalization of two different antigens within specific subcellular structures. Typically, stacks of 20 to 50 optical sections (512 ϫ 512 pixel arrays) with a z-step of 0.2 to 0.5 m between optical sections of single-or dual-stained samples were captured using an HCX PL APO 40X oil immersion objective lens (numerical aperture, 1.25) and an optical zoom factor between 1 and 4. Laser illumination was attenuated, and the pinhole was opened (2 times Airy disc) for improved collection of fluorescence emission signals. Detector gain and offset were adjusted at the beginning of each scan. When necessary, bright field contrast images of immunostained cells and capillaries in tumor-bearing brain sections were also acquired.
For image processing, optical sections were reconstructed into two-dimensional maximum intensity projection images using Leica software. For 3D digital image reconstruction, projection images of single and dual channels were filtered (Gaussian) to reduce noise and processed with Imaris Surpass 3.1 software (Bitplane, Zurich, Switzerland). Volume or isosurface-rendered 3D images of K Ca channel immunoreactive regions in cultured RG2, C6, and 9L rat glioma cells were visualized in "Maximum Intensity Projection" or "Blend" modes. K ؉ Efflux Measurement. For the purpose of demonstrating K Ca channel activity in isolated RBE and RG2 cells (ATCC, Manassas, VA), cells were suspended in 5 ml of growth media (DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 units/ml streptomycin), and approximately 1 ϫ 10 4 cells/well from cell passages 2 to 5 were coated in an eight-well chamber slide. Separately, RBE and RG2 cells were allowed to grow for 24 h to attain a monolayer. The cells were washed twice with potentiometric assay buffer (20 mM HEPES, 120 mM NaCl, 2 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , and 5 mM glucose, pH 7.4) at room temperature just before the assay. The electrode was calibrated with standard concentrations (1-50 M) of KCl. The vehicle (0.5% ethanol in PBS) or NS-1619 (0 -50 M) dissolved in vehicle was added to cells, shaken gently, and incubated for 30 min at 37°C in a CO 2 incubator. Aliquots of assay buffer, adjusted to pH 7.4 and collected at various time points, were injected into a blood-gas diagnostic unit (Bayer Diagnostics, Midfield, MA) to measure K ϩ concentration. The values are expressed in nanomoles per liter.
Membrane Potential Assay. Functional activities of putative K Ca channels in RBE and RG2 cells were measured by detecting changes in voltage across the cell membrane. The procedure is based on the method described by Gopalakrishnan et al. (1999) with some modifications. Instead of a fluorescent membrane potential dye DiBAC 4 (3), we used the membrane potential assay kit provided by manufacturers of the FLEXstation (Molecular Devices). This kit provided a fast, simple, and consistent mix-and-read procedure. In brief, RBE and RG2 cells obtained from cell passages 2 to 5 were suspended in 5 ml of growth media (DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 units/ml streptomycin). The cell density was adjusted to 1 ϫ 10 3 cells/well and coated in sterile clear bottom black 96-well plates (Corning, Inc., Acton, MA), precoated with poly L-Lysine, and allowed to achieve a monolayer within 24 h. The monolayer cells were incubated with the membrane potential assay kit reagents for 30 min and read directly by FLEXstation. The anionic potentiometric dye that traverses between cells and extracellular solution in a membrane potentialdependent manner serves as an indicator of vasomodulator-induced voltage changes across the cell membrane. To determine the optimum dose that elicits detectable voltage changes across RBE and RG2 cell membranes, dose response studies were performed with 0 to 50 M K Ca channel agonist, BK or NS-1619, and K Ca channel antagonist IBTX (10 nM) using the spectrofluorometer (FLEXstation) set to the following parameters; excitation (485 nm), emission (525 nm), and emission cut-off (515 nm) wavelengths. Additionally, the effects of the optimum dose of 10 M BK or NS-1619 and IBTX (10 nM) on K Ca channels activity in RBE and RG2 cells were determined.
Transmission Electron Microscopy. Seven days after RG2 tumor cell implantation, rats were infused intracarotidly with PBS, BK (10 g/kg/min in PBS ϩ 0.5% ethanol), or NS-1619 (2 g/kg/min in PBS ϩ 0.5% ethanol) for 15 min. Rats were infused with 10 ml of cold PBS and perfuse-fixed with 250 ml of 1% glutaraldehyde in PBS, pH 7.4, through the heart. Tumor-bearing brains were removed, and 1-mm 3 tissue pieces encompassing tumor mass, brain surrounding tumor, and normal brain were cut. These samples were immersionfixed in 1% glutaraldehyde at 4°C for 2 h, incubated overnight in 5% sucrose in 0.1 M phosphate buffer at pH 7.4 at 4°C, postfixed in 1% osmium tetroxide for 2 h, dehydrated in ascending ethanol series, propylene oxide, and embedded in Epon. Ultrathin sections were cut from selected blocks, mounted on Formar-coated grids, and double stained with uranyl acetate and lead citrate. For ultrastructural studies on vesicular transport, HRP was used as a tracer. Five minutes after initiating intracarotid infusion of PBS, BK, or NS-1619, 200 mg/kg HRP was injected as an intravenous bolus through the femoral vein. Ten minutes after HRP injection, rats were perfuse-fixed with 2% glutaraldehyde and 2% paraformaldehyde in 0.1 M sodium phosphate, pH 7.4, by cardiac puncture. Forty-micrometer thick vibratome sections of tumor-bearing brain sections were incubated in 5 ml of 0.06 M Tris buffer containing 3,3Ј-diaminobenzidine tetrahydrochloride (0.7 mg/ml) for 30 min at room temperature, followed by a 2-to 3-min treatment in the same buffer containing hydrogen peroxide (0.2 mg/ml). Sections were postfixed in 2% osmium tetroxide in 0.1 M phosphate buffer for 2 h, HRP localized with 3,3Ј-diaminobenzidine-peroxide treatment and observed under a JEOL electron microscope (JEOL, Tokyo, Japan) operating at 80 kV.
Quantitative Analysis. At least 10 profiles of capillaries from each group sectioned transversely and photographed at low magnification (7200ϫ) were evaluated for their general features. Micro-K Ca Channels Regulate BTB Permeability 841 at ASPET Journals on November 13, 2017 jpet.aspetjournals.org graphs were placed on a digitizing screen, and structural features were measured using Scan Pro 4, a computer-assisted image analysis system (Jandel Scientific, Corte Madera, CA). Abluminal and luminal circumferences, areas of endothelial cytoplasm excluding nuclei and vacuoles, and mean thickness of endothelial cytoplasm were measured and compared with those in the control group. The mean thickness of the endothelium was calculated by subtraction of the luminal radius from the abluminal radius, which were obtained from the areas encircled by luminal and abluminal circumferences, respectively. For analysis of vesicles, we selected transversely sectioned capillary profiles, which were defined as vessels having a single, nearly round endothelial cell surrounded by basement membrane. Four test zones of endothelial cytoplasm were photographed at higher magnification (29,000ϫ). They were chosen randomly, typically at the 3, 6, 9, and 12 o'clock positions on the capillary circumference. Three vessels were sampled from each rat, and each treatment group contained 5 to 6 rats to obtain 15 to 18 capillaries per group and a total number of 60 to 72 test zones. Intracytoplasmic vesicles were recognized as bilayered circular organelles with moderate electron density. Invaginations of the luminal or abluminal membrane were counted as vesicles if their neck was narrower than their maximum diameter. The cytoplasmic areas of the test zones, excluding nuclei and vacuoles, were digitally measured on 8 ϫ 10-inch micrographs, and vesicle density was expressed as a number per micrometer squared of cytoplasm. The cumulative area of all vesicles contained in the cytoplasm was also measured to compare it with that of the cytoplasm. The proportion of total vesicular area to the cytoplasmic area was expressed as a percentage, to derive another parameter to characterize vesicular transport.
Cleft Index. Thirty junctional profiles were randomly selected from each group. They were evaluated by measuring the total length of the junctional profile and the cumulative length and area of the junctional clefts, which were areas where the outer leaflets of opposing membranes were not fused. To quantify the degree of opening of tight junctions, we determined two indices: a cleft index and a cleft area index. A cleft index was defined as the proportion of the junctional profile that was composed of clefts. It was expressed in the percentage of the cumulated length of clefts to the total length of junctional profile as described by Stewart et al. (1987) . The cleft area is a translucent zone located between two electron-dense tight junctions and regions of adjacent capillary membranes, which run between the luminal and abluminal surfaces. A cleft area index, which we derived to identify enlarged clefts, was defined as the proportion of the cumulative area of the clefts compared with the total length of the junctional profile. We tested for a significant difference in junctional cleft index among tissue types and between treatment groups.
Statistics. Results are expressed as mean Ϯ S.D. where applicable. For all in vivo permeability studies, we used n Ն 4 rats/group unless otherwise stated. An unpaired two-tailed Student's t test was used to compare the control and treated groups. The statistical analyses of K i , vesicle density, vesicular area, cleft index, and cleft area index comparison among different groups, with or without drug treatment, were performed using analysis of variance followed by either unpaired parametric analysis of Student's t test or by nonparametric analysis of Mann-Whitney's U test. P Ͻ 0.05 was considered statistically significant. The effect of intracarotid infusion of BK or NS-1619 was compared with that of PBS infusions by statistical analysis of the vesicular density and proportion of cumulative vesicular area. Fig. 2A) . The dye delivery was low in control rats infused with PBS. Intracarotid infusion of BK (10 g/kg/min) or NS-1619 (26.66 g/kg/min) for 15 min increased BTB permeability and resulted in enhanced delivery of Evans blue to tumor tissue, without any increase of dye delivery to peritumoral and contralateral normal brain ( Fig.  2A) . The BK-and NS-1619-induced BTB permeability increases were attenuated when coinfused with IBTX ( Fig. 2A ). These results demonstrate that K Ca channels mediate the effects of both BK and NS-1619. The K i was determined for radiotracer [ 14 C]AIB in the tumor core, tumor-adjacent brain tissue, and contralateral brain tissue. Comparison of pseudo-color-enhanced autoradiographs of rat brain sections also showed enhanced delivery of [
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14 C]AIB upon intracarotid infusion of BK or NS-1619 (Fig. 2B) . IBTX coinfusion completely blocked the NS-1619-induced delivery of [ 14 C]AIB; however, blockage of BK-induced effect was partial (Fig. 2B) . BTB permeability, measured as K i (Fig. 2C) , was significantly increased in the tumor center (33.5 Ϯ 6.0 l/g/min; P Ͻ 0.001) by intracarotid infusion of BK (10 g/kg/min) for 15 min compared with PBS controls (8.0 Ϯ 1.5 l/g/min). BK-induced increase in BTB permeability was significantly inhibited (14.4 Ϯ 4.0 l/g/min; P Ͻ 0.01) by coadministration of IBTX at a dose of 0.26 g/kg/min for 15 min (Fig. 2C) . In separate studies, we found that the increases in BTB permeability obtained with a fixed dose of BK (10 g/kg/min) was blocked by coinfusion with IBTX in a dose-dependent manner (Fig. 3A) . The maximum inhibition (Ͼ70%) occurred at 0.26 g/kg/min of IBTX. A higher dose of IBTX, however, did not completely block BKinduced BTB permeability, probably because IBTX is a reversible inhibitor of K Ca channels. In contrast to tumor center, neither BK nor NS-1619, with or without IBTX, affected permeability of the BBB in normal brain surrounding tumor (area within 2 mm of tumor margin) or in normal contralateral brain (Fig. 2) . Similarly, when infused alone or before BK infusion, IBTX did not affect BBB or BTB permeabilities (data not shown).
K Ca Channel Activation and BTB Permeability. Intracarotid infusion of various concentrations of NS-1619 (0 -60 g/kg/min) increased BTB permeability in implanted intracerebral RG2 tumor in a dose-dependent manner (Fig.  3B) . The data were obtained with rats (n ϭ 3) for each dose of NS-1619. The mean arterial blood pressure (MAP) was not significantly affected by intracarotid infusion of NS-1619 at lower doses in rats. At higher doses (Ͼ26.66 g/kg/min), however, a significant drop in MAP was observed (Table 1) . Hence, further studies were performed with a dose of 26.66 g/kg/min, which did not appreciably affect arterial blood pressure. Intracarotid infusion of NS-1619 (26.66 g/kg/min) significantly increased K i (26.5 Ϯ 4.0 l/g/min; P Ͻ 0.001) for [ 14 C]AIB in the tumor center compared with vehicle-administered controls (8.0 Ϯ 1.5 l/g/min) (Fig. 2C) . The NS-1619-induced increase in BTB permeability was significantly in- (Fig. 2C) , indicating a K Ca channel-specific effect.
BTB Permeability Modulation is Generally Independent of CBF. Earlier we showed that infusion of BK (10 g/kg/min) did not alter cerebral blood volume in tumor and normal brain (Liu et al., 2001a) . In the present study, using a laser-operated Doppler, we showed that intracarotid administration of 26.66 g/kg/min of NS-1619 or DEA-NONOate or YC-1 (13.33 g/kg/min) did not significantly affect CBF (Table 1) , but BTB permeability increased in the tumor area (Fig. 2, D and E) . In contrast, infusion of BK (10 g/kg/min) significantly (P Ͻ 0.01) increased CBF compared with the vehicle-administered group. In contrast to increased BTB permeabilities, BBB permeabilities in normal contralateral brain were unaffected by intracarotid infusions of BK, NS-1619, or NS-1619 with IBTX (Fig. 2) .
The NO-cGMP System Modulates BTB Permeability. To investigate whether infusion of NO donors can increase BTB permeability through activation of K Ca channels, RG2 tumor-bearing rats received intracarotid infusion of short-acting NO donors, DEA-NONOate (t 1/2 ϭ 2 min), or PAPA-NONOate (t 1/2 ϭ 15 min) with or without IBTX for 15 min. BTB permeability (K i ) in the tumor center was significantly increased by DEA-NONOate (32 Ϯ 9.0 l/g/min; P Ͻ 0.001) as well as by PAPA-NONOate (36.4 Ϯ 4.0 l/g/min; P Ͻ 0.001) compared with the control group (9.0 Ϯ 2.0 l/g/min) (Fig. 2D) . Coinfused IBTX sig- ]AIB significantly increased after intracarotid infusion of BK (n ϭ 6) or NS-1619 (n ϭ 6) compared with PBS controls (n ϭ 10) and significantly attenuated by coadministration of IBTX (n ϭ 4). D, the mean K i values increased significantly in response to intracarotid infusion of a dose of 26.66 g/kg/min each of DEA-NONOate (DEA-NO; n ϭ 4) or PAPA-NONOate (PAPA-NO; n ϭ 4) compared with PBS-treated controls (n ϭ 6). A cotreatment with IBTX (n ϭ 4) significantly attenuated the effect of both NO donors. E, intracarotid infusion of YC-1 (13.33 g/kg/min, n ϭ 4) increased BTB permeability significantly when compared with PBS group (n ϭ 6). The YC-1-induced K i increase was significantly attenuated by coinfusion of selective inhibitor of sGC, ODQ (10 g/kg/min, n ϭ 4), or IBTX (n ϭ 4). Data in C, D, and E are presented as mean Ϯ S.D. ૺૺૺ, P Ͻ 0.001 versus PBS group; ૺૺ, P Ͻ 0.01 versus agonist-treated group. nificantly attenuated the effect of DEA-NONOate (15.3 Ϯ 2.3 l/g/min; P Ͻ 0.01) and PAPA-NONOate (15.0 Ϯ 1.7 l/g/min; P Ͻ 0.01), demonstrating that NO-sensitive K Ca channels may mediate NO-induced increase in BTB permeability (Fig. 2D) .
A benzylindazole derivative, YC-1, selectively causes a 10-fold increase in sGC activity, significantly increasing intracellular cGMP concentration (Wu et al., 1995) . Since BTB permeability increase is linked to the NO-cGMP system, we investigated whether YC-1 alone could increase K i in a rat tumor model. Indeed, YC-1 increased K i significantly (Fig.  2E ) in the tumor area (29.5 Ϯ 6.0 l/g/min; P Ͻ 0.001) without affecting permeability in brain surrounding tumor or contralateral normal brain compared with vehicle-infused controls (12.0 Ϯ 1.5 l/g/min). A specific inhibitor of sGC, ODQ, coinfused with YC-1 for 15 min, significantly attenuated the YC-1-inducible increase in K i (13.0 Ϯ 3.5 l/g/min; P Ͻ 0.01), demonstrating that YC-1 specifically affects endogenous sGC activity and, subsequently, BTB permeability (Fig. 2E) . In addition, IBTX (0.26 g/kg/min coinfused for 15 min) significantly attenuated YC-1-induced increase in K i (14.0 Ϯ 4.5 l/g/min; P Ͻ 0.01), demonstrating that K Ca channels mediate the effect of YC-1. The effective doses of NO donors and YC-1, which did not affect MAP and CBF, was selected based on qualitative permeability studies performed in rats with RG2 tumor using Evans blue tracer.
Time Course. Permeability studies by QAR in rats bearing RG2 tumor showed that intracarotid infusion of NS-1619 or DEA-NONOate significantly enhanced and sustained delivery of [
14 C]AIB in the tumor center for 30 min (P Ͻ 0.001) and 60 min (P Ͻ 0.01) infusions (Fig. 3C) . In contrast, a 30-and 60-min infusion of BK failed to sustain the initial increase of K i (P Ͻ 0.001) attained at 15 min (Fig. 3C) . Hence, BK-induced K i increase was transient, possibly due to internalization of B2 receptors.
Membrane Potential Assays. The functional activity of putative K Ca channels in a monolayer of RBE and RG2 cells, determined by measuring K ϩ efflux using a sensitive K ϩ electrode of a blood-gas diagnostic unit, increased with the addition of NS-1619 in a dose-dependent manner (Fig. 4A) . Additionally, a decrease in the membrane potential of RBE and RG2 cells in response to the addition of BK or NS-1619, and a return to resting membrane potential with IBTX was measured spectrofluorometrically using a fluorescent probe. Both BK and NS-1619 elicited the depolarization effect in RBE cells (Fig. 4B) . The depolarization actions of BK and NS-1619 were highly pronounced in RG2 (Fig. 4C ) compared with RBE cells (Fig. 4B ). These results demonstrate K Ca channel activation in RBE and RG2 cells in response to BK or NS-1619. In other experiments, we observed that NS-1619 and BK caused a dose-dependent decrease in K ϩ dye-specific fluorescence intensity in both RBE and RG2 cells, which was reversed by IBTX (data not shown).
Immunolocalization of K Ca Channels. We also sought to determine if K Ca channels are differentially and abundantly expressed on tumor cells and tumor capillaries compared with those of normal brain, which might explain the BK-or NS-1619-induced selective BTB permeability increases. Immunoblot experiments with the affinity-purified anti-K Ca channel ␣-subunit antibody reveal higher expression of K Ca channel protein in brain tumor tissue compared with the normal brain tissue, as shown in Fig. 5A . This antibody also recognized K Ca channel ␣-subunit in RG2 cells, RBE cells, and rat brain capillaries (Fig. 5A) . The NIH-1.61-aided immunoblot analyses reveal greater than 4-and 6-fold increase in K Ca channel density in RG2 cells and RG2 tumor, respectively, compared with normal brain (Fig. 5B) . The K Ca Fig. 3 . A, varying doses of IBTX (0, 0.065, 0.13, 0.26, and 0.52 g/kg/min) were used to determine the optimum dose of IBTX that maximally attenuates BK-induced K i increase in rats (n ϭ 3 each dose) with RG2 tumor. IBTX at 0.26 g/kg/min attenuated BK-induced K i increase maximally (Ͼ70%). B, dose-dependent studies showed that the optimal dose of NS-1619 was 26.66 g/kg/min, which caused a significant K i increase in rat tumors (n ϭ 4) without affecting MAP. C, time course study shows that BK-induced K i increase was transient, which lasted for about 15 to 20 min, and at 30 and 60 min BK-induced K i increase was not sustained. In contrast, DEA-NONOate and NS-1619 elicited sustained increases in mean K i values for up to 30 and 60 min, respectively. Data in A, B, and C are presented as mean Ϯ S.D. ૺૺૺ, P Ͻ 0.001 versus PBS group; ૺૺ, P Ͻ 0.01 versus PBS group; ૺ, P Ͻ 0.05 versus PBS group. channel protein levels in RBE cells and brain capillaries were similar to that in normal brain tissue (Fig. 5B) .
We studied localization of K Ca channels in primary RBE cells (Fig. 6 , A-D), cultured RG2 (Fig. 6 , E-J), C6 (Fig. 6K) , and 9L (Fig. 6L ) glioma cells, and in 4% paraformaldehyde perfusion-fixed RG2 glioma-bearing rat brain sections (Fig.  7 , A-C) by immunofluorescence confocal microscopy. The K Ca channel (␣-subunit) expression in RBE cells was primarily confined to the plasma membrane as shown in Fig. 6B . A 3D reconstruction reveals some colocalization of K Ca channels with Factor VIII on the plasma membrane (Fig. 6D) . At high magnification, RG2 cells show K Ca channels confined predominantly to the perinuclear cytoplasmic compartment (Fig. 6, F and H) . To investigate whether other types of rat gliomas also express K Ca channels, we performed immunolocalization on cultured C6 and 9L cells. The confocal 3D construction of C6 (Fig. 6K) and 9L (Fig. 6L ) cells showed abundant expression of K Ca channels. The expression pattern of the K Ca channels in C6 and 9L cells was similar to RG2 cells (Fig. 6, I and J).
We next asked why K Ca channel modulators selectively increase BTB permeability without affecting BBB permeability. One of the reasons for such a selective effect could be due to the overexpression of K Ca channels in tumor tissue compared with normal brain. To address this question, we used anti-K Ca channel (the pore forming ␣-subunit) antibody to immunolocalize K Ca channels in paraformaldehyde perfusion-fixed RG2 tumor-bearing rat brain sections. Wanner et al. (1999) used a similar antibody to localize K Ca channels in rat brain sections. The contralateral brain region shows a faint immunostaining for K Ca channels (Fig. 7A) compared with a high level of K Ca channel expression in the tumor center (Fig. 7B ) and in tumor periphery (Fig. 7C) . Furthermore, at the capillary level, we performed colocalization studies using the primary polyclonal anti-K Ca channel and the monoclonal Factor VIII antibodies with IgG-conjugated FITC and TRITC secondary antibodies, respectively. The results clearly demonstrate that K Ca channels are localized in the endothelia of capillaries located in the tumor periphery (Fig.  8, E-H) . The K Ca channel expression level was relatively higher in the tumor capillary endothelium (Fig. 8, I-L) . In the normal brain capillary, however, K Ca channels were barely detectable (Fig. 8, A-D) . Our observations strongly suggest that the selective effects of BK, NS-1619, NO donors, and YC-1 to increase BTB permeabilities and their attenuation by IBTX are due possibly to increased density distribution of K Ca channels on brain tumor capillary endothelium and tumor cells compared with normal brain cells and normal brain capillary endothelium.
We further investigated whether vesicular transport is largely responsible for enhanced delivery of drugs and macromolecules across the BTB. Double-blind transmission electron microscopy studies, based on a modification of the method described by Joo et al. (1983) and Stewart et al. (1987) , were conducted on endothelia of normal brain capillaries, brain tumor capillaries, and tumor cells. These studies revealed no changes in normal capillary endothelium in the contralateral brain tissue following intracarotid infusion of PBS, BK, or NS-1619 (data not shown). Similarly, PBS infusion did not elicit changes in tumor capillary endothelium (Fig. 9, A and D) or tumor cells (Fig. 9H) . In tumor-bearing rats, however, intracarotid infusion of BK or NS-1619 accelerated formation of pinocytotic vesicles by invagination of the luminal membrane of tumor capillary endothelium and alignment and movement of vesicle arrays along the luminalabluminal axis of the capillary endothelium. These vesicles dock and fuse with basement membrane and release their contents on the abluminal side of the endothelial membrane (Fig. 9, B and C) . In additional experiments using HRP (molecular mass, 40 kDa), numerous vesicles laden with HRP were observed in tumor capillary endothelium (Fig. 9 , E-G) and tumor cells (Fig. 9, I and J) of rats infused with BK or NS-1619 but not in those infused with saline (Fig. 9, D and  H) . These results are consistent with recent evidence that the transcytotic pathway involves both movement of vesicles within the cell and a series of fusions and fissions of the vesicular and cellular membranes (Stewart, 2000) . The quantitative analysis performed by an individual unaware of the sample identity showed that BK significantly increased the density of vesicles per unit surface area of nucleus-free cytoplasm of the brain RG2 tumor capillary endothelium and of the tumor cells compared with PBS control in similar cell types ( Table 2 ). The cleft index, which is indicative of endothelial tight junctions (Stewart, 2000) , was greater in tumor capillary endothelia compared with those of normal brain capillary endothelia. The cleft indices in RG2 tumor capillaries, shown as percent increase (44.40 Ϯ 16.23; P Ͻ 0.01), were significantly higher than in normal brain capillaries (16.00 Ϯ 10.0). These indices (Table 2) , however, were not significantly altered following a 15-min intracarotid infusion of either BK The physiological parameters were determined either before or during the infusion of vasomodulators. The values are mean Ϯ S.D. of n Ն 4 rats, except for CBF where three representative rats per group were used. pH is arterial pH; PaO 2 is arterial oxygen; PaCO 2 is arterial carbon dioxide; and MAP is mean arterial blood pressure. For BTB permeability by QAR, a vasomodulator dose was selected that did not appreciably alter MAP in rats. Data of treated group were significantly different (****P Ͻ 0.001; **P Ͻ 0.01) when compared to control group. (10 g/kg/min) or NS-1619 (26.66 g/kg/min). Similarly, the cleft area indices in RG2 tumor capillaries (8.40 Ϯ 5.40; P Ͻ 0.01) were significantly higher compared with the cleft area indices of normal brain capillaries (1.90 Ϯ 1.30), although these indices were not significantly altered (Table 2) following a 15-min intracarotid infusion of either BK (10 g/kg/ min) or NS-1619 (26.66 g/kg/min). These results demonstrate for the first time that the primary cellular mechanism for macromolecular delivery across the BTB after biochemical modulation is by increased vesicular transport and not by the paracellular route through endothelial tight junctions.
Discussion
The BTB prevents the delivery of most hydrophilic molecules and antitumor agents to brain tumor. Brain tumor capillaries, which surround the BTB, are functionally different from normal brain capillaries (Nishio et al., 1983; Pardridge et al., 1992; Asotra and Black, 2000) . We exploited these differences to selectively enhance drug delivery to brain tumor tissue without affecting normal brain tissue. Here, we used vasomodulators, such as BK, NO donors, sGC activator, and NS-1619, to increase BTB permeability, which significantly enhanced tracer delivery specifically to the brain tumor.
B2 receptors mediate the effects of BK on BTB permeability resulting in enhanced drug delivery selectively to brain tumor (Matsukado et al., 1998) . In our clinical trial, the BK analog RMP-7 produced variable increase in delivery of 68 Ga-EDTA to the tumor of patients with a variety of brain tumors (Black et al., 1997) . This variable response to RMP-7 was possibly due to differences in B2 receptor expression in tumors of those patients. Indeed, in a subsequent study (Liu et al., 2001b) , we demonstrated differential expression of B2 receptors in rat gliomas, which positively correlated with BK-mediated BTB permeability increases. These observations underscore the limitations in the use of BK for a predictable drug delivery and clinical outcome. Moreover, at high doses, BK nonselectively increases BBB permeability (Raymond et al., 1986) . BK-induced BTB permeability increase is also transient, lasting only 20 min (Inamura and 
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Black, 1994), reportedly due to B2 receptor internalization (Pizard et al., 1999) following prolonged BK infusion. In fact, BK-activated downstream signaling targets, such as endogenous NO, sGC, or cGMP, could be independently modulated to elicit a selective and enhanced BTB permeability response ( Figs. 1 and 2 ). More importantly, the present study demonstrates that one can circumvent these signaling pathways and yet selectively increase BTB permeability by directly (Figs. 1 and 2 ). Consistent with our findings, Reiser et al. (1990) showed that BK directly activates K Ca channels in rat glioma cells. BK was also shown to activate K Ca channels through the NO-cGMP system (Zhou et al., 1998) . Furthermore, in our study IBTX attenuated BK-mediated effect on BTB permeability, which is consistent with the observation that IBTX blocks BK-induced cerebral vasodilation (Faraci and Heistad, 1998) . Previously, we demonstrated that infusion of BK did not affect the cerebral blood volume in tumor and normal brain (Liu et al., 2001a) . We showed that intracarotid infusion of NS-1619, DEA-NONOate, or YC-1 at concentrations used in the present study did not significantly alter CBF in the tumor as measured by laser-Doppler flowmetry (Table 1) , with the exception of BK. Hence, the measured increase in K i was not due to the possible change in vasomodulator-induced blood flow but rather due to the direct or indirect effect of these vasomodulators on K Ca channels.
Although the vasodilatory effect of the NO-cGMP system on normal brain macrovasculature is well known, its effect on brain tumor microvasculature permeability is largely unknown. Recent evidence shows that NO activates K Ca channels by both cGMP-dependent (Zhou et al., 1998; Lohse et al., 1998) and cGMP-independent mechanisms (Wu et al., 1995) . Expression of NO synthase in cerebral endothelium and brain tumors has been demonstrated by electrophysiological and immunohistochemical studies (Kitazono et al., 1995) . Consistent with our findings, Zhou et al. (1998) reported that DEA-NONOate activated K Ca channels by modifying the ␣-subunit of the K Ca channels. Recently, we reported (Ningaraj et al., 2000) that K Ca channels mediate the selective BTB permeability increase in rats induced by short-acting NO donors, DEA-NONOate, and PAPA-NONOate. Here, we present further evidence that both endogenous and exogenous NO can directly activate endogenous K Ca channels to modulate BTB permeability. Time course study with NS-1619 and DEA-NONOate demonstrates their ability to elicit enhanced and sustained drug delivery to tumor tissue for up to 60 min (Fig. 3C) , as opposed to the transient effect of BK. Furthermore, vasomodulators at the concentrations we investigated in the current study did not significantly affect physiological parameters (Table 1) .
Although several studies have demonstrated the presence of K Ca channels in cerebrovascular endothelium (Kitazono et al., 1995), none have described the occurrence of K Ca channels (␣-or ␤-subunits) either on brain or tumor capillary endothelium and their possible effect on capillary permeability. To immunolocalize K Ca channels in rat brain sections with RG2 tumor, we used anti-K Ca channel antibody, raised against the ␣-subunit (Wanner et al., 1999) . The immunoblot studies (Fig. 5) demonstrate the abundant expression of K Ca channels in RG2 cells (both in vitro and in vivo) in contrast to cultured endothelial cells and normal brain tissue. However, confocal microscopic analyses reveal abundant expression of K Ca channels (␣-subunits) in rat brain endothelial and tumor cells (Fig. 6 ), tumor tissue (Fig. 7) , and tumor capillaries (Fig.  8 ) compared with normal brain tissue. Moreover, we demonstrated functional activity of K Ca channels in RG2 cells by quantifying BK or NS-1619 -induced K ϩ efflux and membrane potential changes and their reversal by IBTX. In light of these results, we surmise that functional K Ca channels are present and abundantly expressed on RG2 tumor cells and tumor capillaries compared with those of normal brain, which might explain the selective BTB permeability increases caused by BK, NO donors, YC-1, and NS-1619. Because microcapillaries in rat gliomas are biologically different from normal brain capillaries (Nishio et al., 1983) , K Ca channels expressed in tumor capillary endothelium and tumor cells may have altered sensitivity to K Ca channel modulators. Hence, the present data on 1) increases in BTB permeability, 2) functional activity of K Ca channels, and 3) abundance of K Ca channels in tumor capillary endothelium and tumor cells clearly demonstrate that K Ca channels serve as a convergence point in the mechanism that regulates vasomodulator-mediated selective increase in BTB permeability to enhance drug delivery to brain tumor.
We investigated whether increased drug transport across the BTB in response to infusion of either BK or NS-1619 occurs via tumor capillary endothelial tight junctions or through increased vesicle formation. Our results demonstrate that BK and NS-1619 induce accelerated formation of transport vesicles in both brain tumor capillary endothelium and tumor cells. These results provide evidence that vesicular transport is largely responsible for enhanced delivery of drugs across brain tumor capillaries into tumor tissue. Consistent with our observations in rat tumor microvessels, Stewart et al. (1987) reported an increased density of microvessel endothelial vesicles in human brain tumors. Moreover, a relationship between brain capillary endothelial vesicles and macromolecular permeability has been suggested (Stewart, 2000) . Most importantly, our study demonstrates that rat brain tumor microvessels form an even greater number of vesicles in response to vasomodulator infusion, resulting in greater BTB permeability compared with PBS-treated controls. BK (at a low dose), which increases intracellular cGMP , however, did not increase transport vesicle formation in normal capillary endothelium in our studies (Table 2) . Our results are different from a previous study (Joo et al., 1983) , where db-cGMP increased the number of transcytotic vesicles in the normal cerebral capillary endothelium. This difference may relate to the high doses of db-cGMP used by Joo et al. (1983) .
In summary, we have demonstrated in a rat brain tumor model that K Ca channels are the convergence point (Figs. 1 and 2) for BTB permeability modulation by vasomodulators, such as BK, NO donors, YC-1, and NS-1619, that selectively increase permeability in brain tumor capillaries. The K Ca channel-mediated increase in BTB permeability in response to BK or NS-1619 (Fig. 2C) correlates with 1) functional activity of K Ca channels in RBE and RG2 cells (Fig. 4, A-C) , 2) abundance of K Ca channels in tumor cells (Figs. 5 and 6 ), tumor tissue (Figs. 5 and 7) , and tumor capillary endothelium (Fig. 8), 3 ) BK-or NS-1619-induced accelerated transcytotic vesicle formation in brain tumor capillary endothelium (Fig. 9 , B and C); and 4) rapid transport of HRP-laden vesicles across the BTB into tumor cells (Fig. 9, E, I , and J).
Furthermore, K Ca channel-mediated permeability increase in tumor capillaries can be sustained for a longer period with NS-1619 or DEA-NONOate (Fig. 3C) . These findings support a pivotal role for K Ca channels in BTB permeability regulation, besides their previously known role in cerebral vasodilation.
Taken together, our findings demonstrate that K Ca channels are effective targets for BTB permeability modulation. It is conceivable that other types of potassium channels may have some role in BTB permeability regulation (Ningaraj et al., 2001) , which remains to be thoroughly investigated. This study presents evidence that activation of K Ca channels by specific agonists and agents that produce NO and cGMP in situ can sustain enhanced and selective drug delivery to brain tumors. This drug delivery system is independent of B2 receptors and circumvents the disadvantages of BK, specifically variable and refractory BTB permeability responses. In conclusion, our results further delineate the operative mechanisms that regulate BTB permeability for selective and enhanced delivery of molecules across brain tumor microvessels following biochemical modulation. This study may have significant implications for improving targeted delivery of anti-neoplastic agents to brain tumors and neuropharmaceutics to diseased brain regions, while leaving normal brain unaffected.
